CHANGE IN RATINGS

Aetna

(AET)

downgraded at Merrill Lynch from Buy to Neutral. Valuation call, as the stock is up 20% over the past six months.

Baker Hughes

(BHI)

downgraded at Friedman, Billings Ramsey to Market Perform. $96 price target. Valuation looks rich, and the company is growing slower than its peers.

Cardinal Health

(CAH) - Get Report

upgraded at Credit Suisse to Outperform from Neutral based on valuation. Sees favorable risk/reward for the stock. Raised target price to $77 from $74.

Hartford Financial

(HIG) - Get Report

downgraded at Keefe, Bruyette & Woods from Outperform to Market Perform. Valuation call, given the $109 price target. Price competition is already heating up.

Harvest Natural Resources

(HNR)

upgraded to Buy rating from Hold at Jefferies. Price target rockets to $17 from $11 and FY 2008 EPS estimates hold at $1.06.

ManTech International

(MANT) - Get Report

upgraded at Cowen to Outperform rating from Marketperform. FY 2008 EPS estimates raised to $2.15 from $2.14.

Northeast Utilities

(NU)

upgraded at Merrill Lynch to Buy. Stock has pulled back 13% from its April highs. Fundamental growth remains strong, and transmission assets are gaining value.

Office Depot

(ODP) - Get Report

downgraded at JP Morgan from Overweight to Neutral. Company delayed its third quarter earnings, because of an internal vendor review from its audit community.

Office Depot downgraded at Credit Suisse to Underperform from Neutral after company announced the delayed release of Q3 earnings. Lowered target price to $17 from $24.

PharmaNet Development

( PDGI) downgraded at Jefferies to Hold rating from Buy. Price target dips to $37 from $39 while FY 2008 EPS estimates upped to $1.71 from $1.51.

Western Refining

(WNR)

upgraded at UBS to Neutral rating from Sell. Price target and FY 2008 EPS estimates hold at $42 and $2.96, respectively.

Washington Post

(WPO)

upgraded at Deutsche from Hold to Buy. $910 price target. Company has 80% of its EBITDA leveraged to counter-cyclical businesses. Valuation looks attractive, based on growth prospects.

TheStreet Recommends

STOCK COMMENTS / EPS CHANGES

Apache

(APA) - Get Report

price target raised at Goldman to $119 from $115. See additional value in company's international assets, in particular growth opportunities in Australia and Egypt. Note potential multiple expansion based on increasingly global natural gas market and greater credit for Australia oil discoveries.

CVS Caremark

(CVS) - Get Report

price target raised at Goldman to $48 from $43 based on upside to Q3/Q4 earnings as well as potential share buybacks. See healthy operating momentum in both business segments driving additional P/E expansion. Maintained Buy rating.

Dell

(DELL) - Get Report

target increased at Goldman to $35 from $33 based on series of fairly immediate catalysts, including new retail partnerships with

Wal-Mart

and

Staples

, and ongoing favorable DRAM costs, which should keep gross margins higher than anticipated. Maintained Buy rating.

Health Management

(HMA)

2008 estimates lowered at Credit Suisse to 45 cents from 50 cents. Sees little progress towards recovery. Maintained Underperform rating

Ingersoll-Rand

(IR) - Get Report

target upped at Morgan Stanley. IR now seen reaching $61 a share. Company is gaining market share, and the new business mix is driving earnings growth. Equal-weight rating.

ITT

(ITT) - Get Report

target boosted at Morgan Stanley to $68 a share. Company recently posted another strong quarter, and margins should continue to expand. Equal-weight rating.

Joy Global

( JOYG) numbers raised at UBS. Price target jumps to $67 from $55 and FY 2008 EPS estimates lift to $3.15 from $3.05. Reiterates Buy rating.

Lab Corp.

(LH) - Get Report

target reduced at Credit Suisse to $84 from $89 after Q3 results and guidance fell short of estimates. Believes sell-off is overdone. Maintained Outperform rating.

Monsanto

(MON)

target increased at Morgan Stanley to $121 a share. Stock looks undervalued on the sum of the company's assets. Monsanto can sustain 20% annual earnings growth. Overweight rating.

Tesoro

(TSO)

numbers raised at UBS. Price target jumps to $66.50 from $54 while FY 2008 EPS estimates hold at $5.20. Reiterates Buy rating.